Huawei at MWC 2023: Intelligent World Needs Stronger ICT Industry and Digital Economy
28.2.2023 19:41:00 EET | Business Wire | Press release
During MWC Barcelona 2023, Huawei will be meeting with operators, industry partners, and other key opinion leaders from around the world to discuss "GUIDE to the Intelligent World". Together, they will look at how to use the GUIDE business blueprint to lay the foundation for 5.5G and build on the success of 5G for even greater prosperity in an intelligent world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006057/en/
Huawei's Hall 1 exhibition booth at MWC Barcelona 2023 (Photo: Huawei)
Huawei’s main exhibition booth in MWC Barcelona's Hall 1 is designed around the concept of “Intelligent Future, Full of Hope”. At the booth, Huawei painted a picture of an era fueled by the digital economy and defined by collaboration that is more vibrant and full of unlimited possibilities. At the event, Huawei is also showcasing its latest products and solutions that deliver ultimate 5G experiences, premium and intelligent ultra-broadband connectivity, digital and intelligent transformation, and their Green 1-2-3 solution. Huawei's offerings show a clear commitment to innovating for the 5.5G era, creating value for customers, and stimulating the digital economy.
By the end of 2022, 5G had already proven to be a global commercial success, with over a billion mobile users connecting with 5G. Leading operators in China, South Korea, Switzerland, Finland, and Kuwait have already achieved 5G user penetration rates of more than 30%, and more than 30% of their traffic comes from 5G.
According to Ookla's latest 5G City Benchmark Report, Huawei has played an important part in 5G network construction in all of the top 10 cities among the world's 40 representative 5G-enabled cities. It's important to note that 5G performance results in these 10 cities show that the 5G networks constructed by Huawei offer the best experience.
Following on from Huawei's concept of "Striding Towards the 5.5G Era" that was proposed in July 2022, Huawei is highlighting the five major characteristics of the 5.5G era: 10 Gbps experiences, full-scenario interconnection, integrated sensing and communication, L4 autonomous driving networks, and green ICT. Leading global operators, standards organizations, and industry ecosystem partners are coming together to promote innovation and exploration for this 5.5G era, as it will create more new applications and business opportunities.
Ongoing and robust investment into ICT infrastructure directly spurs growth within the digital economy. A third-party report shows that, as new networks evolve from one generation to another, this effect will be further amplified by 15%. Looking towards the future, we believe the GUIDE business blueprint that combines both 5G and 5.5G clearly lays out how ICT evolution will progress and bring about greater value.
Together with our customers and partners, we will continue to innovate, building intelligent connectivity and redefining computing. This collaboration on innovation will create even greater value for the ICT industry and make the industry as a whole more resilient and prosperous.
Huawei’s Enterprise division is also hosting their own event at MWC 2023, themed “Leading Digital Infrastructure for New Value Together”, where they will launch more than 50 innovative products and solutions for global customers. Highlights here include their Intelligent Simplified Campus Network Solution, a series of innovative data center solutions, and business strategies for small- and medium-sized enterprises (SMEs).
In the device field, Huawei is showcasing their new HUAWEI Mate 50 series, HUAWEI WATCH Buds, HUAWEI WATCH GT Cyber, that come packed with new innovation in areas like mobile imaging, fitness and health, and smart office.
MWC Barcelona 2023 runs from February 27 to March 2 in Barcelona, Spain. Huawei showcases its products and solutions at stand 1H50 in Fira Gran Via Hall 1. Together with global operators, industry professionals, and opinion leaders, we dive into topics such as 5G business success, 5.5G opportunities, green development, digital transformation, and our vision of using the GUIDE business blueprint to lay the foundation for 5.5G and build on the success of 5G for even greater prosperity. For more information, please visit: https://carrier.huawei.com/en/events/mwc2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006057/en/
Contact information
Olivia Zhang
+86-15013066795 / +44-7444720703
zhangningning7@huawei.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom